Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: Executive summary

European Heart Journal

Volumn 36, Issue 38, 2015, Pages 2608-2620

  Byrne, Robert A ^a   Serruys, Patrick W ^b   Baumbach, Andreas ^c   Escaned, Javier ^d   Fajadet, Jean ^e   James, Stefan ^f   Joner, Michael ^g   Oktay, Semih ^h   Jüni, Peter ⁱ   Kastrati, Adnan ^a   Sianos, George ^j   Stefanini, Giulio G ^k   Wijns, William ^l   Windecker, Stephan ^k  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Bristol Heart Institute   (United Kingdom)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e CLINIQUE PASTEUR   (France)

^f UPPSALA UNIVERSITY   (Sweden)

^g CVPATH INSTITUTE   (United States)

^h Cardio Med Device Consultants   (United States)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j AHEPA UNIVERSITY HOSPITAL   (Greece)

^k BERN UNIVERSITY HOSPITAL   (Switzerland)

^l CARDIOVASCULAR CENTER   (Belgium)

more..

Author keywords

Bioresorbable stents; Coronary artery disease; Coronary stents; Drug eluting stents; Percutaneous coronary interventions

Indexed keywords

ARTICLE; BARE METAL STENT; BIORESORBABLE STENT; BIORESORBABLE VASCULAR STENT; CARDIOLOGY; CLINICAL ASSESSMENT; CLINICAL DEVELOPMENT PLAN; CLINICAL EVALUATION; CORONARY DRUG ELUTING STENT; CORONARY STENT; DEVICE APPROVAL; DRUG ELUTING CORONARY STENT; EUROPE; EUROPEAN UNION; FOLLOW UP; HUMAN; IN VIVO STUDY; LAW; MEDICAL SOCIETY; METALLIC DRUG ELUTING STENT; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; UNITED STATES; BIODEGRADABLE IMPLANT; CARDIAC IMAGING; CHECKLIST; CORONARY ARTERY DISEASE; DEVICES; DRUG ELUTING STENT; EQUIPMENT DESIGN; LEGISLATION AND JURISPRUDENCE; PRODUCT SAFETY;

ABSORBABLE IMPLANTS; CARDIAC IMAGING TECHNIQUES; CARDIOLOGY; CHECKLIST; CONSUMER PRODUCT SAFETY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; EUROPE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84942024854     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv203     Document Type: Article

References (35)

1. Fraser AG. Clinical evaluation of medical devices: light at the end of the tunnel Eur Heart J 2015;36:64-66.
2. Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. http://eur-lex.europa.eu/LexUriServ/LexUriServ.douri=CONSLEG:1993L0042: 20071011:en:PDF (26 May 2015).
3. Directive 2007/47/EC of the European Parliament and of the council of 5 September 2007 amending council directive 90/385/EEC on the approximation of the laws of the member states relating to active implantable medical devices, council directive 93/42/EEC concerning medical devices and directive 98/8/EC concerning the placing of biocidal products on the market, 2007. http://ec.europa.eu/health/medical-devices/files/revision-docs/2007-47-en-en.pdf (26 May 2015).
4. Fraser AG, Daubert JC, Van de Werf F, Estes NA III, Smith SC Jr, Krucoff MW, Vardas PE, Komajda M, Participants. Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology. Eur Heart J 2011;32: 1673-1686.
5. Committee for Medicinal products for human use (CHMP).Guideline on the clinical and non clinical evaluation during the consultation procedure on medcial substances contained in drug eluting (medical substance-eluting) coronary stents, 2009. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003275.pdf (26 May 15).
6. European Commission. Guidelines on Medical Devices. Evaluation of clinical data-a guide for manufacturers and notified bodies. Appendix 1, 2008. http://ec.europa. eu/health/medical-devices/files/meddev/cetf-en.pdf (26 May 2015).
7. Kramer DB, Kesselheim AS. User fees and beyond-the FDA Safety and Innovation Act of 2012. N Engl J Med 2012;367:1277-1279.
8. FDA. Balancing premarket and postmarket data collection for devices subject to premarket approval. Draft Guidance for Industry and Food and Drug Administration Staff, 2015. http://www.fda.gov/downloads/medicaldevices/deviceregulation andguidance/guidancedocuments/ucm393994.pdf (26 May 2015).
9. FDA. Expedited access for premarket approval medical devices intended for unmet medical need for life threatening or irreversibly debilitating diseases or conditions. Draft Guidance for Industry and Food and Drug Administration Staff. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm393879.htm (26 May 2015).
10. FDA. Investigational Device Exemptions for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human Studies, 2013. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM279103.pdf2 (26 May 2015).
11. Fraser AG, Krucoff MW, Brindis RG, Komajda M, Smith SC Jr. Commentary: international collaboration needed on device clinical standards. BMJ 2011;342:d2952.
12. Di Mario C, James S, Dudek D, Sabate M, Degertekin M. Commentary: the risk of over-regulation. BMJ 2011;342:d3021.
13. Heads of Medicines Agencies (HMA). Guidance document for sponsors for a Voluntary Harmonisation Procedure (VHP) for the assessment of multinational Clinical Trial Applications, 2013. http://www.hma.eu/fileadmin/dateien/Human-Medicines/01-About-HMA/Working-Groups/CTFG/2013-06-CTFG-VHP.pdf (26 May 2015).
14. Reith C, Landray M, Devereaux PJ, Bosch J, Granger CB, Baigent C, Califf RM, Collins R, Yusuf S. Randomized clinical trials-removing unnecessary obstacles. N Engl J Med 2013;369:1061-1065.
15. FDA. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009. www.fda.gov/down loads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (26 May 2015).
16. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA, Waksman R, Weinberger J, Wilensky RL, Jensen DN, Zuckerman BD, Virmani R, Consensus C. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 2002;106:1867-1873.
17. Joner M, Byrne RA. The importance of preclinical research in contemporary interventional cardiology. EuroIntervention 2010;6:19-23.
18. Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, Dangas G, Moses JW, Pucelikova T, Kandzari DE, Ellis SG, Leon MB, Stone GW. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 2008; 51:23-32.
19. Mauri L, Orav EJ, Candia SC, Cutlip DE, Kuntz RE. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005;112:2833-2839.
20. Byrne RA, Eberle S, Kastrati A, Dibra A, Ndrepepa G, Iijima R, Mehilli J, Schomig A. Distribution of angiographic measures of restenosis after drug-eluting stent implantation. Heart 2009;95:1572-1578.
21. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schomig A, Kastrati A. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009;2:291-299.
22. Raber L, Wohlwend L, Wigger M, Togni M,Wandel S,Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Luscher TF, Meier B, Juni P, Windecker S. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 2011;123:2819-2828, 6 p following 2828.
23. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents developed in collaboration with the European Society of Cardiology endorsed by the Society of Cardiac Angiography and Interventions. Eur J Echocardiogr 2001;2:299-313.
24. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, Bouma B, Bruining N, Cho JM, Chowdhary S, Costa MA, de Silva R, Dijkstra J, Di Mario C, Dudek D, Falk E, Feldman MD, Fitzgerald P, Garcia-Garcia HM, Gonzalo N, Granada JF, Guagliumi G, Holm NR, Honda Y, Ikeno F, Kawasaki M, Kochman J, Koltowski L, Kubo T, Kume T, Kyono H, Lam CC, Lamouche G, Lee DP, Leon MB, Maehara A, Manfrini O, Mintz GS, Mizuno K, Morel MA, Nadkarni S, Okura H, Otake H, Pietrasik A, Prati F, Raber L, Radu MD, Rieber J, Riga M, Rollins A, Rosenberg M, Sirbu V, Serruys PW, Shimada K, Shinke T, Shite J, Siegel E, Sonoda S, Suter M, Takarada S, Tanaka A, Terashima M, Thim T, Uemura S, Ughi GJ, van Beusekom HM, van der Steen AF, van Es GA, van Soest G, Virmani R, Waxman S, Weissman NJ, Weisz G, ; International Working Group for Intravascular Optical Coherence Tomography (IWG-IVOCT). Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol 2012;59:1058-1072.
25. Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, Kutys R, Xhepa E, Kastrati A, Virmani R, Joner M. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J 2015;36: 2147-2159.
26. Andreini D, Pontone G, Mushtaq S, Pepi M, Bartorelli AL. Multidetector computed tomography coronary angiography for the assessment of coronary in-stent restenosis. Am J Cardiol 2010;105:645-655.
27. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
28. Hamilos M, Sarma J, Ostojic M, Cuisset T, Sarno G, Melikian N, Ntalianis A, Muller O, Barbato E, Beleslin B, Sagic D, De Bruyne B, Bartunek J, WijnsW. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circ Cardiovasc Interv 2008;1:193-200.
29. Grunkemeier GL, Jin R, Starr A. Prosthetic heart valves: objective performance criteria versus randomized clinical trial. Ann Thorac Surg 2006;82:776-780.
30. Byrne RA, Kastrati A. Drug-eluting stent trials: too much non-inferiority, too little progress Lancet 2014;383:386-388.
31. Lauer MS, D'Agostino RB Sr. The randomized registry trial-the next disruptive technology in clinical research N Engl J Med 2013;369:1579-1581.
32. FDA (CDRH C, HHS). Draft Guidance for Industry: Coronary Drug-Eluting Stents-Nonclinical and Clinical Studies. Washington, DC, USA; 2008. http://www.fda. gov/downloads/Drugs/Guidances/UCM072196.pdf (26 May 15).
33. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351.
34. Avorn J. Two centuries of assessing drug risks. N Engl J Med 2012;367:193-197.
35. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel system-a national resource for evidence development. N Engl J Med 2011;364:498-499.